Biocardia, Inc. (BCDA) 8-K Summary
Business Context and Reporting Period
Biocardia, Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 12, 2025. The filing serves to announce the company's financial results for the quarter ended September 30, 2025. The company's common stock and warrants trade on The Nasdaq Capital Market under the symbols BCDA and BCDAW, respectively.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release (Exhibit 99.1) but does not embed the financial data within the 8-K text itself.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The report references an external press release for the specific operational and financial comparisons.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2025) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the quarter ended September 30, 2025, as they are not present in the 8-K body.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the referenced press release.
- Confirm the company's cash runway and burn rate from the full press release to assess liquidity risks.